To further evaluate BTZ effects on the cytotoxic effects of chemotherapy drugs, we tested the anti-cancer activity of BTZ and doxorubicin combination in 13 primary tumor cell samples isolated from B-cell lymphoma patients (Figure 6A and 6B). Here, CASC3 is linked to B-cell non-Hodgkin lymphoma.